All In Biotech

Drug Trial Radar · NCT05648500

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 470 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

470

Actual

Start

Dec 13, 2022

Primary completion

Mar 31, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Viatris Innovation GmbHIndustry
Sponsor type
Industry
First posted
Dec 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to severe symptoms. The main questions it aims to answer are: * How well cenerimod works on top of the treatment already being administered. * How safe cenerimod is for adult patients with Systemic Lupus Erythematosus. Researchers will compare one dose of cenerimod and a placebo to see how well cenerimod works when it is added to the treatment already being administered. In this research study approximately 210 participants will receive cenerimod and approximately 210 participants will receive placebo for 12 months.

Conditions

  • Lupus Erythematosus, Systemic

Interventions

  • CenerimodDrug

    Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.

  • PlaceboDrug

    Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Month 12 compared to baselineTime frame: At Month 12 compared to Day 1 (pre-dose baseline)

Locations

198 sites in 17 countries. Site status is shown where the registry gives one.

  • California Research Institute

    Huntington Park, California

  • University of Colorado Denver

    Aurora, Colorado

  • Clinical Research of West Florida, Inc.

    Clearwater, Florida

  • Omega Research MetroWest, LLC

    DeBary, Florida

  • Alloy Clinical Research, LLC

    Kissimmee, Florida

  • SouthCoast Research Center, Inc.

    Miami, Florida

  • Allied Biomedical Research Institute

    Miami, Florida

  • Professional research Center INC

    Miami, Florida

  • IRIS Research and Development, LLC

    Plantation, Florida

  • Augusta University

    Augusta, Georgia

  • Advance Quality Medical Research

    Orland Park, Illinois

  • Accurate Clinical Research Inc. - Lake Charles

    Lake Charles, Louisiana

  • Louisiana State University School of Medicine section of Rheumatology

    New Orleans, Louisiana

  • Axon Clinical Research -Baltimore

    Baltimore, Maryland

  • Bronx Care Health and Wellness Center

    The Bronx, New York

  • DJL Clinical Research, PLLC

    Charlotte, North Carolina

  • University of Oklahoma College of Medicine

    Oklahoma City, Oklahoma

  • Accurate Clinical Research Inc.

    Baytown, Texas

  • Rheumatology Care Center, PLLC

    Bellaire, Texas

  • Houston MD Medspa and Wellness Clinic

    Houston, Texas

  • Accurate Clinical Research Inc.

    Houston, Texas

  • Sun Research Institute

    San Antonio, Texas

  • Fundación Respirar

    Buenos Aires, Argentina

  • Instituto Medico CER

    Buenos Aires, Argentina

  • Aprillus Asistencia e Investigacion

    Buenos Aires, Argentina

  • Arsema Clinica Adventista Belgrano

    Buenos Aires, Argentina

  • IR Medical Center /Hospital de Día/ Instituto de Reumatología y Traumatología

    Mendoza, Argentina

  • Instituto CAICI SRL

    Rosario, Argentina

  • Centro de investigaciones medicas Tucuman

    San Miguel de Tucumán, Argentina

  • Centro Integral de Reumatología

    San Miguel de Tucumán, Argentina

  • ICT (Investigaciones Clínicas Tucumán)

    San Miguel de Tucumán, Argentina

  • Santa Casa de Belo Horizonte

    Belo Horizonte, Brazil

  • Centro Mineiro de Pesquisas

    Juiz de Fora, Brazil

  • Instituto Méderi de Pesquisa e Saúde

    Passo Fundo, Brazil

  • Centro Multidisciplinar de Pesquisa Clínica (Irmandade da Santa Casa de Misericórdia de Porto Alegre

    Porto Alegre, Brazil

  • LMK Servicos Medico S/S

    Porto Alegre, Brazil

  • IMPAR SERVICOS HOSPITALARES S/A ; Hospital São Lucas

    Rio de Janeiro, Brazil

  • SER - Serviços Especializados em Reumatologia da Bahia

    Salvador, Brazil

  • Hospital de Clínicas de Porto Alegre

    Santa Cecília, Brazil

  • Centro Multidiciplinar de Estudos Clínicos- CEMEC

    São Bernardo do Campo, Brazil

Showing 40 of 198 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.